RT Journal Article
SR Electronic
T1 Myasthenia gravis therapy: immunoadsorbent may eliminate need for plasma products
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 60
OP 64
VO 60
IS 1
A2 Ben H. Brouhard
A1 Koji Sawada
A1 Paul S. Malchesky
A1 Anna P. Koo
A1 Hiroshi Mitsumoto
YR 1993
UL http://www.ccjm.org/content/60/1/60.abstract
AB This in vitro study assessed the effectiveness of a new immunoadsorbent (Asahi IM-TR 350) in removing anti-acetylcholine receptor antibody from plasma with minimal loss of albumin. Plasma procured from a myasthenia gravis patient undergoing routine plasma exchange was perfused through the immunoadsorbent and recirculated in vitro to simulate a clinical treatment. To assess the temperature dependency of sorption, perfusion was performed at various temperatures. Plasma solute concentrations were taken before and after perfusion to calculate solute rejection coefficients. The immunoadsorbent has a high sorption capacity for anti-acetylcholine receptor antibody, while allowing a minimum loss of albumin. For patients with myasthenia gravis, this immunoadsorbent can provide an alternative to plasma exchange that does not require the use of plasma products.